Trial Profile
A Phase I, Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of DHES0815A in Patients With HER2-Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jan 2022
Price :
$35
*
At a glance
- Drugs DHES-0815A (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions; First in man
- Sponsors Genentech
- 13 Jul 2021 Status changed from active, no longer recruiting to completed.
- 31 Jul 2020 Planned End Date changed from 30 Apr 2020 to 30 Apr 2022.
- 31 Jul 2020 Planned primary completion date changed from 30 Apr 2020 to 30 Apr 2022.